A detailed history of Price T Rowe Associates Inc transactions in Organon & Co. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 163,228 shares of OGN stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163,228
Previous 153,002 6.68%
Holding current value
$2.49 Million
Previous $3.17 Million 1.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.65 - $23.03 $190,714 - $235,504
10,226 Added 6.68%
163,228 $3.12 Million
Q2 2024

Aug 14, 2024

BUY
$17.45 - $21.96 $136,057 - $171,222
7,797 Added 5.37%
153,002 $3.17 Million
Q1 2024

May 15, 2024

BUY
$13.78 - $18.8 $130,785 - $178,430
9,491 Added 6.99%
145,205 $2.73 Million
Q4 2023

Feb 14, 2024

SELL
$10.95 - $17.32 $2.34 Million - $3.7 Million
-213,819 Reduced 61.17%
135,714 $1.96 Million
Q1 2023

May 15, 2023

BUY
$21.42 - $32.08 $199,034 - $298,087
9,292 Added 2.73%
349,533 $8.22 Million
Q4 2022

Feb 14, 2023

BUY
$23.31 - $28.61 $70,769 - $86,859
3,036 Added 0.9%
340,241 $9.5 Million
Q3 2022

Nov 14, 2022

SELL
$23.4 - $34.25 $95,425 - $139,671
-4,078 Reduced 1.19%
337,205 $7.89 Million
Q2 2022

Aug 15, 2022

SELL
$31.66 - $38.9 $5.51 Million - $6.77 Million
-173,955 Reduced 33.76%
341,283 $11.5 Million
Q1 2022

May 16, 2022

SELL
$30.45 - $39.36 $710,916 - $918,937
-23,347 Reduced 4.33%
515,238 $18 Million
Q4 2021

Feb 14, 2022

SELL
$28.67 - $37.13 $143,091 - $185,315
-4,991 Reduced 0.92%
538,585 $16.4 Million
Q3 2021

Nov 15, 2021

SELL
$28.63 - $35.64 $6.32 Million - $7.86 Million
-220,665 Reduced 28.87%
543,576 $17.8 Million
Q2 2021

Aug 16, 2021

BUY
$28.45 - $38.0 $21.7 Million - $29 Million
764,241 New
764,241 $23.1 Million

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.89B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.